Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

ABCs Areas

ABCs Population

The surveillance areas represent 31,711,122 persons. Source: U.S. Bureau of the Census, 1999

ABCs Case Definition

Invasive meningococcal disease: isolation of Neisseria meningitidis from normally sterile site in a resident of a surveillance area in 1999.

ABCs Methodology

Project personnel communicated at least monthly with contacts in all microbiology laboratories serving acute care hospitals in their area to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Molecular subtyping was done on meningococcal isolates at CDC. Regular laboratory audits assess completeness of active surveillance and detect additional cases.

All rates of invasive meningococcal disease were calculated using U.S. Bureau of the Census postcensal population estimates for 1999.

For national projections of cases, race- and age-specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the 1999 U.S. population.

Cases with unknown race were distributed by area based on reported race distribution for known cases within the eight age categories.

Reported ABCs Profiles

Race

No.

(Rate*)

White

247

(1.0)

Black

85

(1.6)

Other

15

(0.9)

Total

347

(1.1)

Unknown race (n=40) distributed amongst knowns

* Cases per 100,000 population for ABCs areas

Syndrome

CasesNo. (%*)

DeathsNo. (Rate†)

Meningitis

162 (46.7)

17 (10.5)

Bacteremia without focus

139 (40.1)

18 (12.9)

*Percent of cases.

†Deaths per 100 cases with known outcome

SerogroupsAge (years)

SerogroupsBNo. (Rate*)

SerogroupsCNo. (Rate*)

SerogroupsYNo. (Rate*)

SerogroupsOtherNo. (Rate*)

<1

26 (6.0)

8 (1.8)

16 (3.7)

4 (0.9)

1

4 (0.9)

2 (0.5)

2 (0.5)

1 (0.2)

2-4

15 (1.2)

12 (0.9)

3 (0.2)

4 (0.3)

5-17

15 (0.3)

28 (0.5)

18 (0.3)

3 (0.1)

18-34

23 (0.3)

26 (0.3)

17 (0.2)

7 (0.1)

35-49

11 (0.1)

6 (0.1)

14 (0.2)

7 (0.1)

50-64

6 (0.1)

2 (0.04)

11 (0.2)

6 (0.1)

≥ 65

8 (0.2)

7 (0.2)

25 (0.7)

10 (0.3)

Total

108 (0.3)

91 (0.3)

106 (0.3)

42 (0.1)

*Cases per 100,000 population for ABCs areas

Serogroup B IsolatesSerosubtypes

Serogroup B IsolatesNo. (%)

Serogroup B IsolatesSerotypes: Serosubtype

Serogroup B IsolatesNo. (%)

P1.7,16

12 (24)

15:P1.7,16

11 (22)

P1.22a,14

9 (18)

NT:P1.22a,14

6 (12)

P1.4

4 (8)

2A:P1.5,2

3 (6)

P1.5,2

4 (8)

4,7:P1.4

3 (6)

P1.6

3 (6)

14:NT

2 (4)

P1.7,1

3 (6)

4,7:P1.7,1

2 (4)

*Oregon isolates not included due to continuing increase of P1.7,16

National Projection for Invasive Disease

Cases: 2,957 (1.1/100,000)Deaths: 316 (0.1/100,000)

Healthy People 2010 Update

Objective: Reduce the incidence of invasive meningococcal disease to 0.9 per 100,000 population.